Genomma Lab Internacional (LABB) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
26 Feb, 2026Executive summary
2025 saw a significant deceleration in Mexican consumption and internal execution gaps, leading to a deliberate reduction in sell-in to normalize retailer inventories; like-for-like sales declined 4.3% year-over-year, with Q4 like-for-like sales down 12.9%.
Despite the downturn, underlying consumer demand remained resilient, with Q4 Mexico sell-out down only 2.2%.
Productivity savings of over MXN 1 billion were unlocked and reinvested in growth initiatives such as product innovation and distribution expansion.
EBITDA margin for 2025 was 23.4%, up 43 basis points, reflecting strong cost containment and operational resilience.
Management expects early 2026 to show higher OPEX and softer sales, with growth initiatives gaining traction in the second half and a disciplined reset for sustainable growth.
Financial highlights
Consolidated net sales for 2025 were MXN 17,541.2 million, down 5.7% year-over-year; Q4 net sales were MXN 4,017.0 million, down 13.9%.
Gross profit margin was 62.8% for 2025, down from 64.1% in 2024.
Full year EBITDA was MXN 4,100.9 million (23.4% margin), down 4.0% year-over-year; Q4 EBITDA was MXN 886.6 million (22.1% margin), down 16.5%.
Full year net income was MXN 1,607.4 million, down 23.1% year-over-year, mainly due to non-cash Forex losses from Argentine peso depreciation.
Free cash flow reached MXN 1,507 million, down 45.5% due to higher CapEx, lower net income, and higher tax payments.
Outlook and guidance
2026 guidance: EBITDA margin expected at 23%-23.5%, with a return to 24% in 2027 as operating leverage improves.
Q1 2026 expected to be flat or low single-digit growth as inventory normalization completes; gradual top-line recovery anticipated from Q2 onward.
CapEx for 2026 projected at MXN 250–270 million, mainly for maintenance and innovation.
Cash flow in 2026 expected to improve due to lower CapEx and normalized tax payments.
Growth initiatives include product innovation, distribution expansion, enhanced in-store execution, and stronger communication.
Latest events from Genomma Lab Internacional
- Double-digit sales, margin, and EPS growth, with record free cash flow and strong regional gains.LABB
Q4 20243 Feb 2026 - Q2 2024 delivered strong profit, margin expansion, and double-digit EPS growth.LABB
Q2 20242 Feb 2026 - Q3 2024 delivered double-digit sales and profit growth, margin expansion, and record cash flow.LABB
Q3 202418 Jan 2026 - Q1 2025 saw strong sales, margin expansion, and robust free cash flow despite market headwinds.LABB
Q1 202528 Nov 2025 - EBITDA margin rose to 23.8% and free cash flow surged 65% despite FX headwinds.LABB
Q2 202516 Nov 2025 - Sales and profits declined, but strong margins and cost controls support a 2026 recovery.LABB
Q3 202524 Oct 2025